Moleac logo.png
Moleac’s NeuroAiD™II Improves Post-Concussion Symptoms, Quality of Life, and Mood after a Mild Traumatic Brain Injury
04 déc. 2023 22h41 HE | Moleac Pte Ltd
Promising results from the SAMURAI study show NeuroAiDTMII significantly improves post-concussion symptoms, QoL and mood post-mild traumatic brain injury.
Moleac logo.png
SLT (CognivAiD™) Improves Memory and Cognition in Individuals With Mild Cognitive Impairment: Clinical Trial Results
09 nov. 2023 04h22 HE | Moleac Pte Ltd
Investigator-initiated clinical trial of SLT (CognivAiDTM) for mild cognitive impairment (MCI) reported significant improvement in key cognitive domains.
Moleac launches CognivAiD™, a novel targeted product for vascular dementia
16 janv. 2023 04h02 HE | Moleac Pte Ltd
CognivAiD provides a long-awaited option to fulfil the unmet needs of patients with vascular dementia. CognivAiD demonstrated significant and clinically meaningful disease-modifying benefits in...